Size | Price | Stock | Qty |
---|---|---|---|
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
Other Sizes |
|
Purity: ≥98%
Zalcitabine (trade name Hivid) is a nucleoside analog HIV reverse transcriptase inhibitor (NARTI). It is an antiviral pyrimidine nucleoside analogue effective against HIV replication. 2′,3′-Dideoxycytidine, when activated to its triphosphate, is incorporated into DNA by HIV-1 RT (HIV-1 reverse transcriptase), causing DNA chain termination and viral replication. Zalcitabine was the third antiretroviral to be approved by the Food and Drug Administration (FDA) for the treatment of HIV/AIDS. It is used as part of a combination regimen. Zalcitabine appears less potent than some other nucleoside RTIs, has an inconvenient three-times daily frequency and is associated with serious adverse events. For these reasons it is now rarely used to treat human immunodeficiency virus (HIV), and it has even been removed from pharmacies entirely in some countries.
ln Vitro |
Zalcitabine is an antiviral drug that is phosphorylated to 2',3'-dideoxycytidine 5'-triphosphate (ddCTP) in both HIV-positive and uninfected cells. Zalcitabine is a dideoxynucleoside. Reverse transcriptase is inhibited and proviral DNA chain elongation is stopped when ddCTP is used at therapeutic dosages to prevent HIV replication[1]. With an IC50 value of 1.23 mM, zelcitabine inhibits the cellular absorption of [3H]-PAH in CHO/hOAT1 cells. Additionally, when hOATI activity in CHO/hOAT1 cells rose, zalcitabine's cellular absorption increased threefold[2].
|
||
---|---|---|---|
ln Vivo |
|
||
Animal Protocol |
|
||
References |
[1]. Adkins JC, et al. Zalcitabine. An update of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of HIV infection.Drugs. 1997 Jun;53(6):1054-80
[2]. Jin MJ, et al. Interaction of zalcitabine with human organic anion transporter 1. Pharmazie. 2006 May;61(5):491-2. |
Molecular Formula |
C9H13N3O3
|
|
---|---|---|
Molecular Weight |
211.22
|
|
CAS # |
7481-89-2
|
|
SMILES |
O1[C@]([H])(C([H])([H])O[H])C([H])([H])C([H])([H])[C@]1([H])N1C(N=C(C([H])=C1[H])N([H])[H])=O
|
|
InChi Key |
WREGKURFCTUGRC-POYBYMJQSA-N
|
|
InChi Code |
InChI=1S/C9H13N3O3/c10-7-3-4-12(9(14)11-7)8-2-1-6(5-13)15-8/h3-4,6,8,13H,1-2,5H2,(H2,10,11,14)/t6-,8+/m0/s1
|
|
Chemical Name |
4-amino-1-((2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
|
|
Synonyms |
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
---|
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 4.7344 mL | 23.6720 mL | 47.3440 mL | |
5 mM | 0.9469 mL | 4.7344 mL | 9.4688 mL | |
10 mM | 0.4734 mL | 2.3672 mL | 4.7344 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.